Long‐Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
- 14 August 2026
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 117 (6) , 1562-1572
Abstract
Background: Long‐term treatment with Bruton's tyrosine kinase inhibitors has substantially improved outcomes in chronic lymphocytic leukemia (CLL). However, real‐world evidence simultaneously evaluating clinical outcomes, treatment adherence, persistence, and adverse event management remains limited. This study assessed long‐term treatment dynamics and clinical outcomes in patients with CLL receiving ibrutinib in routine clinical practice. Methods: We conducted a multicenter, retrospective, observational study involving four Italian centers. Adult patients with CLL treated with ibrutinib between January 2016 and June 2024 were included. Clinical records were linked with hospital pharmacy dispensing registries to evaluate progression‐free survival (PFS), overall survival (OS), time to treatment discontinuation (TTD), adherence, persistence, and adverse event management. Adherence was calculated using dispensing data adjusted according to the prescribed daily dose (PDD). Kaplan–Meier analyses were performed for survival outcomes, while multivariable logistic and Cox regression models were used to identify factors associated with adherence and clinical outcomes. Results: A total of 276 patients were included (47% first‐line, 36% second‐line, and 17% third‐line or later therapy). Mean age was 70 ± 10 years and 63% were male. Adherence remained consistently high across treatment lines and throughout follow‐up, with mean adherence values generally ranging between 0.75 and 0.90. At 8 years, first‐line patients achieved PFS, OS, and TTD rates of 86.4%, 64.5%, and 61.4%, respectively. Corresponding estimates were 72.7%, 49.5%, and 23.1% in second‐line patients and 95.8%, 49.4%, and 53.5% among patients receiving third‐line or later therapy. Adverse drug reactions occurred in 53% of patients; 74% resolved following clinical management. Higher comorbidity burden (CIRS > 6) was independently associated with optimal adherence (OR 2.12, 95% CI 1.12–4.00; p = 0.016) and lower risk of treatment discontinuation (HR 0.36, 95% CI 0.16–0.80; p = 0.013). Conclusions: Long‐term treatment with ibrutinib was associated with favorable clinical outcomes, sustained adherence, and prolonged treatment persistence in routine clinical practice. Proactive adverse event management and individualized treatment optimization may contribute substantially to maintaining long‐term treatment exposure and maximizing clinical benefit.Keywords
This publication has 18 references indexed in Scilit:
- Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemiaExpert Review of Hematology, 2026
- Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines AgencyBlood Cancer Journal, 2023
- Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemiaLeukemia & Lymphoma, 2022
- Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database AnalysisClinical Drug Investigation, 2021
- Ibrutinib for Chronic Lymphocytic Leukemia with TP53 AlterationsNew England Journal of Medicine, 2020
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyLeukemia, 2019
- Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular ResponseActa Haematologica, 2016
- Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies AheadActa Haematologica, 2016
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaJAMA Oncology, 2015
- Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE projectBlood, 2010